

Provisional Draft Agenda
Biocides Working Group Meeting I-2021
15-25 March 2021

WG-I-2021 meetings are held as virtual meetings via WebEx

The time is indicated in Helsinki time.

Mon 15 March	10:00-17:00	APCP WG
Tue 16 March	10:00-17:00	APCP WG
Wed 17 March	10:00-17:00	APCP WG
Tue 16 March	10:00-17:00	TOX WG
Wed 17 March	10:00-17:00	TOX WG
Thu 18 March	10:00-17:00	TOX WG
Thu 18 March	10:00-17:00	EFF WG
Tue 23 March	10:00-17:00	EFF WG
Thu 25 March	10:00-17:00	EFF WG
Wed 24 March	10:00-17:00	ENV WG
Thu 25 March	10:00-17:00	ENV WG

Analytical methods and physico-chemical properties Working Group		
Chair: Bernhard Krebs		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes of WG IV 2020 <i>WG IV 2020_APCP_6-1</i> <i>WG IV 2020_APCP_Gen agenda items</i>		<i>For agreement</i>
Item 6 – Training (closed session)		
Item 7 – Outcome of e-consultations (closed session)		
Item 8 - Discussion of Active Substances		eCA
8.1	L-(+)-lactic acid PT 06 Meeting document: <i>WG I 2021_APCP_8-1</i>	DE <i>For agreement</i>
Item 9 - Discussion of Union Authorisations		eCA
9.1	UA for product containing Permethrin PT 18 (BC-GK024706-40) Meeting document: <i>WG I 2021_APCP_9-1</i>	DK <i>For agreement</i>
9.2	UA for product containing active chlorine released from chlorine PT 02, 05 (BC-UQ045679-98) Meeting document: <i>WG I 2021_APCP_9-2</i>	BE <i>For agreement</i>
9.3	UA for product containing active chlorine released from sodium hypochlorite PT 02 (BC-ER045796-14) Meeting document: <i>WG I 2021_APCP_9-3</i>	BE <i>For agreement</i>
Item 10 - Technical and guidance related issues		
Item 11 – AOB		

Human Health Working Group		
Chair: Antero Airaksinen		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-IV-2020		
<ul style="list-style-type: none"> • WG-IV-2020_TOX_6-1 • WG-IV-2020_TOX_6-2 • WG-IV-2020_TOX_7-1 • WG-IV-2020_TOX_Minutes 		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	L-(+)-lactic acid PT 6 Meeting document: <i>WGI2021_TOX_6-1</i>	DE
<i>For agreement</i>		
6.2	Sulfur dioxide released from sodium metabisulfite – ED Assessment PT 9 Meeting documents: <i>WGI2021_TOX_6-2</i>	DE
<i>For agreement</i>		
Item 7 - Discussion of Union Authorisations		eCA
7.1	UA for product containing Permethrin PT 18 (BC-GK024706-40) Meeting document: <i>WGI2021_TOX_7-1</i>	DK
<i>For agreement</i>		
7.2	UA for product containing active chlorine released from chlorine PT 2, 5 (BC-UQ045679-98) Meeting document: <i>WGI2021_TOX_7-2</i>	BE
<i>For agreement</i>		

7.3	UA for product containing active chlorine released from sodium hypochlorite PT 2 (BC-ER045796-14) Meeting document: <i>WGI2021_TOX_7-3</i> <i>For agreement</i>	BE
Item 8 – Discussion of mutual recognition		eCA
8.1	Request to ECHA for an opinion pursuant to Articles 36(2) and 38 of the BPR Meeting document: <i>WGIV2020_TOX_8-1</i> <i>For agreement</i>	FR
Item 9 - Technical and guidance related issues		Presenter
9.1	Update on guidance development Meeting document: <i>WGI2021_TOX_9-1</i> <i>For discussion</i>	SECR
9.2	Proposal for a new TAB entry on local effects Meeting document: <i>WGI2021_TOX_9-2</i> <i>For agreement</i>	DE
9.3	Review of TAB Meeting document: <i>WGI2021_TOX_9-3</i> <i>For agreement</i>	SECR
9.4	Dermal absorption of rodenticides Meeting document: <i>WGI2021_TOX_9-4</i> <i>For agreement</i>	DE
Item 10 – AOB		Presenter
10.1	Other information & lessons learned Meeting document: <i>WGI2021_TOX_10-1</i> <i>For discussion</i>	SECR

Environment Working Group Chair: Heike Schimmelpfennig		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes of WG-IV-2020		
<ul style="list-style-type: none"> • WG-IV-2020_ENV_6-1 • WG-IV-2020_ENV_6-2 • WG-IV-2020_ENV_7-1 • WG-IV-2020_ENV_General_minutes 		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	L-(+)-lactic acid PT 06 Meeting document: <i>WGI2021_ENV_6-1</i> <div style="text-align: right;"><i>For agreement</i></div>	DE
6.2	Post-approval data for OIT PT 06, 07, 09, 10, 11 and 13 + PT 08 submission to BPC Meeting document: <i>WGI2021_ENV_6-2</i> <div style="text-align: right;"><i>For agreement</i></div>	FR
Item 7 - Discussion of Union Authorisations		eCA
7.1	UA for product containing Permethrin PT 18 (BC-GK024706-40) Meeting document: <i>WGI2021_ENV_7-1</i> <div style="text-align: right;"><i>For agreement</i></div>	DK
7.2	UA for product containing active chlorine released from chlorine PT 02, 05 (BC-UQ045679-98) Meeting document: <i>WGI2021_ENV_7-2</i> <div style="text-align: right;"><i>For agreement</i></div>	BE

7.3	UA for product containing active chlorine released from sodium hypochlorite PT 02 (BC-ER045796-14) Meeting document: <i>WGI2021_ENV_7-3</i> <i>For agreement</i>	BE
Item 8 – Technical and guidance related issues		Presenter
8.1	Overview on guidance Meeting document: <i>WGI2021_ENV_8-1</i> <i>For information</i>	SECR
8.2	TAB database new entries - open questions Meeting document: <i>WGI2021_ENV_8-2</i> <i>For agreement</i>	SECR
8.3	Development of Chesar platform – status and open questions Meeting document: <i>WGI2021_ENV_8-3</i> <i>For information/agreement</i>	SECR
8.4	CEPE study: semi-field leaching tests for PT 7 Meeting document: <i>WGI2021_ENV_8-4</i> <i>For information</i>	CEPE
Item 9 – AOB		
9.1	Other information & lessons learned SECR to inform <i>For information</i>	SECR
9.2	Meeting the timelines: alternative ways of working Meeting document: <i>WGI2021_ENV_9-2</i> <i>For discussion</i>	SECR

Efficacy Working Group		
Chair: Katarzyna Szymankiewicz		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda <i>For agreement</i>		
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-IV-2020 <ul style="list-style-type: none"> • WG-IV-2020_EFF_6-1 • WG-IV-2020_EFF_7-1 • WG-IV-2020_EFF_Minutes <i>For agreement</i>		
Item 6 – Discussion of Active Substances		eCA
6.1	L-(+)-lactic acid PT 06 Meeting document: <i>WGI2021_EFF_6-1</i> <i>For agreement</i>	DE
Item 7 - Discussion of Union Authorisations		eCA
7.1	UA for product containing Permethrin PT 18 (BC-GK024706-40) Meeting document: <i>WGI2021_EFF_7-1</i> <i>For agreement</i>	DK
7.2	UA for product containing active chlorine released from chlorine PT 02, 05 (BC-UQ045679-98) Meeting document: <i>WGI2021_EFF_7-2</i> <i>For agreement</i>	BE
7.3	UA for product containing active chlorine released from sodium hypochlorite PT 02 (BC-ER045796-14) Meeting document: <i>WGI2021_EFF_7-3</i> <i>For agreement</i>	BE

7.4	<p>Early WG on UA-APP containing Margosa extract from cold-pressed oil of the kernels of Azadirachta Indica extracted with super-critical carbon dioxide PT 19 (BC-TV050221-21) Meeting document: <i>WGI2021_EFF_7-4</i></p> <p style="text-align: right;"><i>For agreement</i></p>	FR
Item 8 - Technical and guidance related issues		
8.1	<p>Vol. II, Parts B+C – PT1-5 Meeting document: <i>WGI2021_EFF_8-1</i></p> <p style="text-align: right;"><i>For discussion</i></p>	ECHA
8.2	<p>TAB proposals</p> <ul style="list-style-type: none"> • PT14: Efficacy data for products with a lowered active substance concentration Meeting document: <i>WGI2021_EFF_8-2a</i> • PT18: Crack and crevice treatment test (closed session) Meeting document: <i>WGI2021_EFF_8-2b</i> <p style="text-align: right;"><i>For discussion</i></p>	DE/NL
8.3	<p>Resistance assessment guidance of biocidal antimicrobial active substances and products Meeting document: <i>WGI2021_EFF_8-3</i></p> <p style="text-align: right;"><i>For discussion</i></p>	FR
8.4	<p>Requirements for insecticide and repellent treated articles Meeting document: <i>WGI2021_EFF_8-4</i></p> <p style="text-align: right;"><i>For information</i></p>	SE
Item 9 – AOB		
9.1	<p>Other information & lessons learned Meeting document: <i>WGI2021_EFF_9-1</i></p> <p style="text-align: right;"><i>For information</i></p>	ECHA